Citigroup
PLRX icon

Citigroup’s Pliant Therapeutics PLRX Stock Holding History

Citigroup’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,000
Closed -$387K – 5731
2024
Q1 		$387K Sell
26,000
-3,900
-13% -$64.3K ﹤0.01% 3706
2023
Q4 		$541K Buy
+29,900
New +$455K ﹤0.01% 3350

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Citigroup's PLRX Position: Q4 2025 in Review

Citigroup sold out of Pliant Therapeutics (PLRX) in Q4 2025, closing a stake of 4,319 shares — an estimated $6.39K sold.

Citigroup first reported a position in PLRX in Q3 2020 and held it in 21 quarters. The position peaked at $3.18M in Q1 2024. 96 funds tracked by Wall St. Rank hold PLRX as of Q4 2025.

  • Citigroup reported no remaining Pliant Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 4,319 Pliant Therapeutics shares in Q4 2025, an estimated $6.39K.
  • Citigroup first reported a position in Pliant Therapeutics in Q3 2020 and held it in 21 quarters.
  • Citigroup's Pliant Therapeutics position peaked at $3.18M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.